Bluebird Historical Balance Sheet

BLUE Stock

USD 0.42 0.01 2.44%

Trend analysis of Bluebird bio balance sheet accounts such as Other Current Liab of 8.6 M, Total Current Liabilities of 114.3 M or Total Stockholder Equity of 184.8 M provides information on Bluebird Bio's total assets, liabilities, and equity, which is the actual value of Bluebird bio to its prevalent stockholders. By breaking down trends over time using Bluebird Bio balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Bluebird bio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bluebird bio is a good buy for the upcoming year.

Bluebird Bio Inventory

24.06 Million

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

About Bluebird Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Bluebird bio at a specified time, usually calculated after every quarter, six months, or one year. Bluebird Bio Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Bluebird Bio and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Bluebird currently owns. An asset can also be divided into two categories, current and non-current.

Bluebird Bio Balance Sheet Chart

At present, Bluebird Bio's Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 287 M, whereas Total Current Liabilities is forecasted to decline to about 114.3 M.

Total Assets Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Bluebird Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Bluebird bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Bluebird Bio balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bluebird bio are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Bluebird Bio's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Bluebird bio current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bluebird bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.At present, Bluebird Bio's Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 287 M, whereas Total Current Liabilities is forecasted to decline to about 114.3 M.

	2021	2022	2023	2024 (projected)
Other Current Liabilities	78.5M	52.0M	9.0M	8.6M
Total Assets	593.8M	554.9M	619.2M	1.1B

Other Current Liab Total Assets

Bluebird Bio balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.71	0.64	0.96	0.7	0.74	0.56	-0.42	-0.24	0.56	0.78	0.87	0.61	0.6	0.95	0.55	0.13	0.92	0.64	0.38	0.54	0.69	0.69	0.95	-0.07	0.45
Other Current Liab	0.71		0.77	0.68	0.47	0.76	0.31	-0.17	-0.41	0.66	0.36	0.68	0.82	0.81	0.7	0.56	0.01	0.79	0.56	0.71	0.56	0.72	0.72	0.69	-0.15	0.37
Total Current Liabilities	0.64	0.77		0.51	0.26	0.91	0.14	0.16	-0.79	0.85	0.37	0.73	0.97	0.98	0.51	0.89	0.54	0.55	0.72	0.45	0.89	0.93	0.92	0.53	0.42	0.8
Total Stockholder Equity	0.96	0.68	0.51		0.79	0.6	0.67	-0.61	-0.02	0.45	0.78	0.8	0.47	0.46	0.99	0.44	-0.13	0.95	0.51	0.36	0.33	0.55	0.55	0.98	-0.29	0.24
Other Liab	0.7	0.47	0.26	0.79		0.36	0.62	-0.5	0.26	0.24	0.45	0.65	0.23	0.22	0.73	0.18	-0.35	0.82	0.26	0.39	-0.01	0.28	0.3	0.72	-0.39	-0.03
Property Plant And Equipment Net	0.74	0.76	0.91	0.6	0.36		0.15	0.13	-0.7	0.73	0.43	0.81	0.92	0.92	0.59	0.82	0.46	0.64	0.91	0.48	0.83	0.98	1.0	0.62	0.39	0.75
Current Deferred Revenue	0.56	0.31	0.14	0.67	0.62	0.15		-0.78	0.29	0.14	0.71	0.29	0.03	0.03	0.71	0.12	-0.33	0.57	-0.03	0.05	-0.08	0.06	0.1	0.68	-0.48	-0.05
Net Debt	-0.42	-0.17	0.16	-0.61	-0.5	0.13	-0.78		-0.57	0.08	-0.7	-0.03	0.23	0.24	-0.63	0.14	0.62	-0.47	0.22	-0.04	0.36	0.2	0.18	-0.65	0.71	0.37
Retained Earnings	-0.24	-0.41	-0.79	-0.02	0.26	-0.7	0.29	-0.57		-0.61	-0.06	-0.43	-0.8	-0.8	-0.03	-0.82	-0.82	-0.03	-0.58	-0.23	-0.95	-0.74	-0.74	-0.04	-0.79	-0.92
Accounts Payable	0.56	0.66	0.85	0.45	0.24	0.73	0.14	0.08	-0.61		0.3	0.63	0.86	0.86	0.46	0.68	0.35	0.51	0.56	0.1	0.7	0.76	0.73	0.46	0.31	0.6
Cash	0.78	0.36	0.37	0.78	0.45	0.43	0.71	-0.7	-0.06	0.3		0.43	0.26	0.26	0.79	0.4	0.08	0.58	0.33	0.13	0.32	0.38	0.4	0.85	-0.11	0.33
Non Current Assets Total	0.87	0.68	0.73	0.8	0.65	0.81	0.29	-0.03	-0.43	0.63	0.43		0.73	0.72	0.75	0.67	0.28	0.83	0.73	0.35	0.66	0.79	0.78	0.72	0.18	0.58
Non Currrent Assets Other	0.61	0.82	0.97	0.47	0.23	0.92	0.03	0.23	-0.8	0.86	0.26	0.73		1.0	0.47	0.84	0.47	0.56	0.75	0.49	0.88	0.93	0.93	0.48	0.4	0.75
Other Assets	0.6	0.81	0.98	0.46	0.22	0.92	0.03	0.24	-0.8	0.86	0.26	0.72	1.0		0.46	0.85	0.49	0.54	0.75	0.48	0.88	0.94	0.93	0.47	0.41	0.76
Cash And Short Term Investments	0.95	0.7	0.51	0.99	0.73	0.59	0.71	-0.63	-0.03	0.46	0.79	0.75	0.47	0.46		0.41	-0.13	0.94	0.5	0.35	0.33	0.55	0.54	0.98	-0.33	0.21
Common Stock Total Equity	0.55	0.56	0.89	0.44	0.18	0.82	0.12	0.14	-0.82	0.68	0.4	0.67	0.84	0.85	0.41		0.55	0.39	0.62	0.3	0.88	0.82	0.85	0.44	0.57	0.89
Common Stock Shares Outstanding	0.13	0.01	0.54	-0.13	-0.35	0.46	-0.33	0.62	-0.82	0.35	0.08	0.28	0.47	0.49	-0.13	0.55		-0.17	0.46	0.01	0.78	0.54	0.51	-0.09	0.86	0.82
Short Term Investments	0.92	0.79	0.55	0.95	0.82	0.64	0.57	-0.47	-0.03	0.51	0.58	0.83	0.56	0.54	0.94	0.39	-0.17		0.55	0.49	0.32	0.59	0.58	0.91	-0.34	0.17
Non Current Liabilities Total	0.64	0.56	0.72	0.51	0.26	0.91	-0.03	0.22	-0.58	0.56	0.33	0.73	0.75	0.75	0.5	0.62	0.46	0.55		0.34	0.7	0.92	0.91	0.52	0.39	0.6
Other Current Assets	0.38	0.71	0.45	0.36	0.39	0.48	0.05	-0.04	-0.23	0.1	0.13	0.35	0.49	0.48	0.35	0.3	0.01	0.49	0.34		0.31	0.42	0.45	0.38	-0.15	0.2
Other Stockholder Equity	0.54	0.56	0.89	0.33	-0.01	0.83	-0.08	0.36	-0.95	0.7	0.32	0.66	0.88	0.88	0.33	0.88	0.78	0.32	0.7	0.31		0.86	0.86	0.35	0.68	0.95
Total Liab	0.69	0.72	0.93	0.55	0.28	0.98	0.06	0.2	-0.74	0.76	0.38	0.79	0.93	0.94	0.55	0.82	0.54	0.59	0.92	0.42	0.86		0.99	0.56	0.43	0.76
Property Plant And Equipment Gross	0.69	0.72	0.92	0.55	0.3	1.0	0.1	0.18	-0.74	0.73	0.4	0.78	0.93	0.93	0.54	0.85	0.51	0.58	0.91	0.45	0.86	0.99		0.57	0.44	0.78
Total Current Assets	0.95	0.69	0.53	0.98	0.72	0.62	0.68	-0.65	-0.04	0.46	0.85	0.72	0.48	0.47	0.98	0.44	-0.09	0.91	0.52	0.38	0.35	0.56	0.57		-0.29	0.25
Short Term Debt	-0.07	-0.15	0.42	-0.29	-0.39	0.39	-0.48	0.71	-0.79	0.31	-0.11	0.18	0.4	0.41	-0.33	0.57	0.86	-0.34	0.39	-0.15	0.68	0.43	0.44	-0.29		0.8
Common Stock	0.45	0.37	0.8	0.24	-0.03	0.75	-0.05	0.37	-0.92	0.6	0.33	0.58	0.75	0.76	0.21	0.89	0.82	0.17	0.6	0.2	0.95	0.76	0.78	0.25	0.8

Click cells to compare fundamentals

Bluebird Bio Account Relationship Matchups

Bluebird Bio balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.7B	1.8B	593.8M	554.9M	619.2M	1.1B
Other Current Liab	141.6M	180.1M	78.5M	52.0M	9.0M	8.6M
Total Current Liabilities	223.6M	203.6M	153.0M	128.2M	200.1M	114.3M
Total Stockholder Equity	1.3B	1.4B	374.3M	196.3M	194.5M	184.8M
Other Liab	58.0M	48.0M	54.6M	93K	107.0K	101.6K
Property Plant And Equipment Net	337.1M	346.9M	101.2M	291.4M	267.0M	174.1M
Current Deferred Revenue	18.9M	11.6M	2.3M	1.5M	1.4M	1.3M
Net Debt	(136.2M)	(124.7M)	(71.6M)	168.4M	193.6M	203.3M
Retained Earnings	(2.3B)	(2.9B)	(3.7B)	(4.0B)	(4.3B)	(4.0B)
Accounts Payable	43.0M	13.8M	25.9M	14.9M	18.5M	15.1M
Cash	327.2M	317.7M	161.2M	113.0M	221.8M	287.0M
Non Current Assets Total	575.3M	565.7M	257.3M	355.4M	337.5M	352.4M
Non Currrent Assets Other	79.2M	72.8M	53.3M	52.1M	54.3M	35.0M
Other Assets	79.2M	72.8M	53.3M	52.1M	59.9M	33.2M
Cash And Short Term Investments	1.2B	1.3B	396.6M	181.7M	209.0M	198.6M
Common Stock Total Equity	547K	554K	665K	711K	817.7K	431.4K
Common Stock Shares Outstanding	55.2M	62.2M	68.9M	78.6M	192.8M	202.4M
Short Term Investments	531.6M	982.7M	779.2M	833.5M	138.3M	67.3M
Liabilities And Stockholders Equity	1.7B	1.8B	593.8M	554.9M	638.1M	1.1B
Non Current Liabilities Total	218.9M	222.6M	66.5M	230.3M	224.5M	161.3M
Other Current Assets	45.7M	522.2M	25.6M	8.6M	9.9M	9.4M
Other Stockholder Equity	3.6B	4.3B	4.1B	4.2B	4.8B	5.1B
Total Liab	442.4M	426.2M	219.5M	358.6M	424.6M	275.6M
Property Plant And Equipment Gross	337.1M	346.9M	121.6M	313.3M	308.9M	181.3M
Total Current Assets	1.2B	1.2B	336.5M	199.5M	281.7M	267.6M
Accumulated Other Comprehensive Income	(1.9M)	(5.5M)	(2.9M)	(4.1M)	(3.7M)	(3.8M)
Short Term Debt	20.2M	9.7M	46.3M	88.2M	101.5M	106.6M
Common Stock	554K	665K	711K	830K	954.5K	1.0M
Property Plant Equipment	151.2M	162.8M	101.2M	291.4M	335.1M	351.8M
Net Tangible Assets	1.3B	1.3B	368.6M	185.8M	213.7M	203.0M
Net Receivables	12.8M	2.4M	11.4M	10.8M	22.2M	23.3M
Retained Earnings Total Equity	(1.5B)	(2.3B)	(2.9B)	(3.7B)	(3.3B)	(3.2B)
Capital Surpluse	3.4B	3.6B	4.3B	4.1B	4.7B	2.6B
Inventory	(144.3M)	(149.7M)	(108.5M)	(1.4M)	22.9M	24.1M
Non Current Liabilities Other	218.9M	222.6M	93K	92K	105.8K	100.5K
Intangible Assets	14.3M	10.0M	5.6M	4.9M	10.4M	10.8M
Long Term Investments	506.1M	131.5M	122.9M	97.1M	1.4M	0.0

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

When determining whether Bluebird bio is a strong investment it is important to analyze Bluebird Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bluebird Bio's future performance. For an informed investment choice regarding Bluebird Stock, refer to the following important reports:

How To Invest In Bluebird

Details

Is Bluebird Stock a good investment?

Details

What is Bluebird Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Bluebird Stock refer to our How to Trade Bluebird Stock guide.

You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bluebird Bio. If investors know Bluebird will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bluebird Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.80)

Revenue Per Share

0.357

Quarterly Revenue Growth

1.337

Return On Assets

(0.36)

Return On Equity

(1.87)

The market value of Bluebird bio is measured differently than its book value, which is the value of Bluebird that is recorded on the company's balance sheet. Investors also form their own opinion of Bluebird Bio's value that differs from its market value or its book value, called intrinsic value, which is Bluebird Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bluebird Bio's market value can be influenced by many factors that don't directly affect Bluebird Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bluebird Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bluebird Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bluebird Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bluebird Historical Balance Sheet

Bluebird Bio Inventory

24.06 Million

About Bluebird Balance Sheet Analysis

Bluebird Bio Balance Sheet Chart

Total Assets

Total Current Liabilities

Bluebird Bio balance sheet Correlations

Bluebird Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bluebird Bio balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Other Assets	+ 1.0	Non Currrent Assets Other
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.99	Total Liab
Other Assets	+ 0.98	Total Current Liabilities
Total Current Assets	+ 0.98	Total Stockholder Equity

Other Stockholder Equity	- 0.95	Retained Earnings
Common Stock	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.82	Retained Earnings
Common Stock Total Equity	- 0.82	Retained Earnings
Other Assets	- 0.8	Retained Earnings
Non Currrent Assets Other	- 0.8	Retained Earnings